header logo image


Page 314«..1020..313314315316..320330..»

Is the Pro-Life Movement on a Collision Course with the Coronavirus? – The Dispatch

November 2nd, 2020 3:51 am

Amid the news explosion that followed President Trumps COVID-19 diagnosis and brief convalescence earlier this month, there was a nugget you might have missed: The antibody treatment from biotech company Regeneron the president tookseemingly to great effecthad been developed in part by means of cells derived from fetal tissue.

Most of the discussion around this revelation concerned whether it showed the president to be a hypocriteeither personally because of his stated pro-life beliefs, or as a matter of policy because his administration has suspended federal funding for scientific research involving fetal tissue. (Both claims were dubious: There was no reason to believe the president knew the provenance of the Regeneron cocktail when he was treated with it, and the kind of fetal-derived cells used to develop the drug were not included in the administrations funding freeze.)

But the news portended a larger problem that may prove important in months to come: the ethical objections other pro-life people may have to new COVID treatmentsincluding vaccineswith similar issues in their development history.

I think its going to test our convictions about these things, said Dr. C. Ben Mitchell, a professor of moral philosophy at evangelical Union University and senior fellow at the Center for Bioethics & Human Dignity. Whether or not we are going to be consistent with our convictions.

Beyond the central aim of ending legal abortion, no issue has so united the pro-life movement over the last few decades as the push to prevent fetal and embryonic remains from being used in medical research. In the 2000s, the battle involved embryonic stem cell research: President Bush prohibited federal funding for research involving new embryonic stem cell lines in 2001, a policy President Obama reversed in 2009. More recently, the issue has been researchers use of fresh tissue from recent abortions, following activist David Daleidens 2015 expos on Planned Parenthoods practice of selling organs from aborted fetuses to medical research companies.

But while pushing for public policy changes and supply chain reforms to make researchers less reliant on ongoing abortions, pro-lifers have also struggled with a parallel issue on a more personal level: whether its permissible to make use of treatments developed via the use of fetal tissue that already exist. If abortion is evil, they ask themselves, then can I in good conscience allow myself to benefit from medicines that rely on the practice?

Such questions are complicated by the fact that, unlike the tissue research that has dominated pro-life policy space in recent years, many medical products in current use, including a number of childhood vaccines, have a connection to abortion that is distant and tenuous. The cell cultures used in developing such medicines are most accurately described not as fetal cells themselves, but as cells that are fetal-derived: Cells originally taken from an aborted fetus that have been cultivated to multiply freely ever since.

The most widely used of these cell lines date back to just a handful of abortions in Europe in the 1960s. The WI-38 cell line, which has been used to develop vaccines for rubella, rabies, measles, mumps, and various other diseases, is derived from the lung tissue of a fetus aborted in Sweden in 1962; The MRC-5 line, used to produce vaccines for Hepatitis A and polio, dates back to 1966. Other lines are used for other purposes: HEK293 cells, which are derived from fetal kidney cells isolated in the Netherlands in the early 1970s, can be used to create virus-like cells that arent able to infect humans. Researchers use these pseudoviruses to test new therapeutics without having to handle live virus themselves, reducing the need for extreme biosafety precautions in laboratory settings. (The aforementioned Regeneron made use of HEK293 cells in this way.)

These cell cultures wont reproduce infinitely, but saying so almost feels like a technicality: Descendants of the WI-38 and MRC-5 lines have been used to create hundreds of millions of doses of vaccines over the past half-century.

Going by any sort of costbenefit analysis, the use of these cell lines has been a force for good in the world. By making use of the remains of a bare handful of elective abortionsabortions that would have taken place whether or not researchers decided to use thema staggering number of people around the world have been spared the miseries of a whole host of wretched and deadly diseases.

But for those who advocate for decoupling from such practices, simply to use the language of cost and benefit in the first place is to give away the game. If thats the measure, they argue, its hard to see how you could oppose any promising medical research, even the most depraved: How can you weigh the suffering of a few unfortunates against the ongoing benefits to all humanity of curing a deadly disease?

These sorts of ethical questions arent the exclusive domain of the pro-life movement. What posture we ought to take toward ill-gotten medical research is a question that has long occupied bioethicists, given how much of the science underpinning our current understanding and practice of medicine was conducted in unethical waysoften even by the standards of their own time, and even more so by the more exacting standards of the present.

The classic example, of course, is the gruesome human experimentation carried out by Nazi doctors in concentration camps, but there are examples closer to home, too: black men in Alabama whose untreated syphilis was allowed to fester for decades so government researchers could observe the progress of the disease, all the while assuring the subjects they were being treated; developmentally disabled children in New York given chocolate milk laced with feces to deliberately infect them with hepatitis as part of an effort to develop a vaccine.

Other ethical issues involve the origin of immortalized cell cultures in particular. The longevity of these cell lines is such that many of them predate modern medical standards on ethical human research, which werent truly codified until the National Commission for the Protection of Human Subjects of Biomedical and Behavior Research, established by Congress for the purpose in 1974, published its Belmont Report in 1979. The oldest such cell line in existence is a culture of cervical cancer cells taken from a woman named Henrietta Lacks in 1951, who died of the disease that same year. Lacks never consented to having her cells cultured; nor did the women who obtained the abortions that resulted in the WI-38 or MRC-5 cells.

These fraught ethical issues are not a thing of the past. After decades of lobbying, the Lacks family finally won a partial concession from the National Institutes of Health in 2013 to place some restrictions on medical access to information about their relatives cells. Pro-life organizations continually push for researchers to divest from and seek alternatives to fetal cell cultures as well.

For some pro-life bioethicists, the vast distance between the harm of the original abortion and the use of the modern treatment in which it resulted means that, while policymakers and biotech firms still have a moral obligation to work toward developing ethically unproblematic alternatives, individuals dont necessarily have a moral duty to abstain from such treatments themselves. Medical ethics are complicated and a matter of conscience, said Tiffany Manor, who directs the Life Ministry of the conservative Lutheran ChurchMissouri Synod. Some modern medical procedures result from past research that was conducted unethically. That doesnt mean that we ought to throw out all of the beneficial procedures.

But others argue that individuals retain a moral duty to keep pressure on the medical research industry by declining the use of such treatments when possible without creating grave risks to public health. The Catholic Churchs Pontifical Academy for Life tried to strike such a balance when it considered the question in 2005:

On a cultural level, the use of such vaccines contributes in the creation of a generalized social consensus to the operation of the pharmaceutical industries which produce them in an immoral way. Therefore, doctors and fathers of families have a duty to take recourse to alternative vaccines (if they exist), putting pressure on the political authorities and health systems so that other vaccines without moral problems become available. They should take recourse, if necessary, to the use of conscientious objection with regard to the use of vaccines produced by means of cell lines of aborted human foetal origin.

The document goes on:

As regards the diseases against which there are no alternative vaccines which are available and ethically acceptable, it is right to abstain from using these vaccines if it can be done without causing children, and indirectly the population as a whole, to undergo significant risks to their health.

You can see the precarious moral tightrope here: It is good, in the mind of pro-life ethicists, to attempt as much as possible not to participate, however indirectly, in the evil act of a long-ago abortion. But one ought not strain so hard to avoid that participation that one thoughtlessly commits another evil act: allowing oneself or ones children to become vectors of otherwise preventable disease, spreading suffering and even death to those around them.

All this, remember, is just the moral calculus that surrounds such vaccine under normal medical circumstances. Throw in a global pandemic and an unprecedented race to treat and cure it, and you begin to get a sense of the scale of the ethical headaches involved.

Take the issue of Regeneron. Since his own positive experience with the companys antibody cocktail, REGN-COV2, President Trump has become its biggest cheerleader; pushing for it to play a major role in COVID treatment going forward. We have hundreds of thousands of doses that are just about ready. I have emergency use authorization all set, he said on October 7. Youre gonna get better, and youre gonna get better really fast.

But both Regenerons drug and a similar antibody treatment currently being developed by Eli Lilly made use of fetal tissue in their developmentnot in the actual manufacture of the drug, as mentioned above, but in creating neutered pseudoviruses to test its effectiveness.

Imagine a person whose doctor has recommended such a drug trying to make a decision in the light of the moral principles suggested by the Pontifical Academy for Life. On the one hand, the drug is a product of fetal tissue research in only the most remote possible way. But the possibility of endangering others by abstaining does not bear considering here, as the cocktail is a treatment, not a vaccine. Further, it is unclear how a person recommended such a treatment by a doctor ought to think about the question of whether there are ethically acceptable alternatives. Other drugs can help manage COVID, of course, but generally speaking their effect is cumulative: Dexamethasone and remdesivir are not replacements for antibody therapy.

To cap the dilemma off, it isnt as though a pro-life person could start off with unproblematic treatments and work up to REGN-COV2 as a matter of last resort: Patients arent prescribed antivirals or steroids for COVID unless theyre already seriously sick, while antibody treatments like Regenerons have been shown to be helpful only if theyre given very early in the course of the disease, before the bodys own immune response has had a chance to kick in.

COVID vaccines in development present further difficulties. First, we dont actually know which of the many vaccines currently being developed will end up the first to pass muster as a safe, effective, and mass-producible weapon against the pandemic. Many of the candidates do not make use of fetal-derived cells in any capacity. Others use such cells only in confirmatory tests, as with Regeneron. Still others use them in the production of the vaccines themselves.

Of the four vaccines seemingly closest to release in America, twothose being developed by Pfizer and Modernawere merely tested on fetal-derived cells. Two others, from Johnson & Johnson and AstraZeneca, are made with them. The latter vaccines Phase III clinical trials were placed on hold earlier this month, but were resumed last week.

Under ordinary circumstances, this would be a no-brainer: Many pro-life people would simply wait for one of the less objectionable vaccines to become available. But during the coronavirus pandemic, where every day that goes by without a vaccine is critical, what happens if Johnson & Johnson or AstraZenecas product is first past the post, and the federal government invests heavily in its development and distribution?

Its unclear whether such a situation would provoke a legal clash. The federal government doesnt have the constitutional authority to mandate vaccines, but states and cities can; all 50 states require children to receive a battery of vaccines before attending public school, although all offer various exemptions for religious, philosophical, and/or other reasons. Whether citizens have a right to such exemptions, however, is less clear: the Supreme Court has upheld mandatory vaccination programs in the past and has separately ruled that the right to practice religion freely does not include liberty to expose the community or the child to communicable disease.

Theres no reason to believe yet that states will choose to go that route. New York Gov. Andrew Cuomo, whose state was racked by the coronavirus this spring and who last year signed a state law ending religious exemptions for childhood vaccines, is thus far messaging that an eventual COVID vaccine will be available to all New York residents who want one.

The likelier scenario may be that such a clash will instead simply play out in the court of public opinion.

One of the nightmare scenarios Ive been thinking about is, say we get a safe and effective vaccine, and it comes from what many would regard as tainted sources, said Mitchell. And so pro-lifers decide not to use the vaccinethey wont be vaccinated. My guess is that there would be a huge uprising in the society saying, Well, youre posing now a public health risk. We now have a vaccine, but youre choosing not to use it. Youre exposing others to it by not taking the vaccine, or youre going to cost our health care system huge amounts of money in treating you when we have a vaccine that could prevent getting COVID-19, but you choose not to. So I think those are going to be an important test of our convictions.

Photograph by Paul Hennessy/NurPhoto/Getty Images.

Read more:
Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch

Read More...

Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm’s US Manufacturing Facility…

November 2nd, 2020 3:51 am

PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ --Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner toexpedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn (autologous MSC-NTF) in the U.S.

BrainStorm is investigating NurOwn as a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). BrainStorm's most advanced clinical program for NurOwn is in ALS, which is currently being evaluated in a pivotal Phase 3 clinical trial.

BrainStorm seeks to locate, design and construct a new commercial manufacturing facility in the U.S. to prepare for potential commercialization. RR&D, a three-firm services alliance consisting of EwingCole, Facility Logix and Biggins, Lacy, Shapiro & Company, will identify the location and develop the design of BrainStorm's new commercial manufacturing facility.

"We're thrilled to be working with BrainStorm on this project and to have the opportunity to deliver this critical work to our region," said EwingCole CEO, Jared Loos, PE, AIA. "We embrace the spirit of creating potentially life-changing technology and we will do everything we can to move the project forward in an efficient and yet responsible manner."

BrainStorm intends to use the facility primarily for cell therapy production. RR&D will provide custom, streamlined project management, site selection analysis and design/construction management services throughout the project's lifecycle.

Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics commented, "Our decision to partner with RR&D was driven by the strong capabilities of the individual partners and their holistic approach to planning, site selection and design services. The expansion of BrainStorm's manufacturing capabilities is a key part of our broader corporate strategy to prepare for potential regulatory approvals of NurOwn and becoming a commercial organization. This new partnership follows our recently announced agreement with Catalent Pharma Solutions to manufacture NurOwn at a scale large enough to meet potential commercial needs at the time of launch. The dedicated, state-of-the-art manufacturing facility developed by RR&D will provide us with important long-term autonomy and strategic flexibility, including the capacity to supply NurOwn for additional disease indications beyond ALS. Together these two partnerships will help ensure that BrainStorm has the manufacturing capacity to meet the needs of patients today and well into the future."

Site selection analyses will begin immediately with the goal of identifying locations that offer a cost-effective solution for BrainStorm's new manufacturing facility. At the same time, the design team will begin developing a conceptual design of the manufacturing facility, based upon input from BrainStorm's process, engineering, and scientific staff, by defining the main steps of the production process and Current Good Manufacturing Practices (cGMP) requirements. The approximately 50,000 square-foot building will contain manufacturing suites, complementary support and infrastructure, and the ability to expand the facility to 100,000 square feet to anticipate future programmatic needs.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website atwww.brainstorm-cell.com.

About Rapid Reshore & Development:

Rapid Reshore & Development is an alliance of expert firms providing confidence and support throughout the life sciences industry, representing an evolution from transaction-driven service models to a holistic focus on client needs, integrating an interdisciplinary team customized for a variety of individual projects. To optimize and strengthen confidence in decision-making and speed-to-market, Rapid Reshore & Development alliance was formed to deliver best-in-class professionals with deep experience in all aspects of life sciences' project planning, site selection, design and execution including financial, labor market, development incentives, real estate, design and engineering, and construction management.For additional information, visit: http://www.rapidreshore.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Brainstorm:Investor Relations: Corey Davis, Ph.D. LifeSci Advisors, LLC Phone: +1 646-465-1138[emailprotected]

Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768[emailprotected]

Rapid Reshore & Development (RR&D):Media Contact:Zachary DeRitisCommunications Specialist215-409-4249[emailprotected]

SOURCE BrainStorm Cell Therapeutics Inc.; Rapid Reshore & Development (RR&D)

Go here to read the rest:
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's US Manufacturing Facility...

Read More...

Will Trevor Lawrence stay at Clemson to avoid the Jets? – Yahoo! Voices

November 2nd, 2020 3:51 am

GlobeNewswire

BEIJING, China, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Li Auto Inc. (Li Auto or the Company) (Nasdaq: LI), an innovator in Chinas new energy vehicle market, today announced that in October 2020 the Company delivered 3,692 Li ONEs, representing a steady increase compared to September. In October, the Company also achieved strong orders, setting a new monthly record. 2020 Q12020 Q22020 Q32020 JanOct Deliveries2,8966,6048,66021,852 As of October 31, 2020, the Company had 41 retail stores covering 36 cities. Going forward, the Company plans to continue strengthening its direct sales and servicing network to further bolster its footprint and market penetration in China.About Li Auto Inc.Li Auto Inc. is an innovator in Chinas new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric SUVs. Through innovative products, technology, and business model, the Company provides customers with safe, convenient, and cost-effective mobility solutions. Li Auto is the first to successfully commercialize extended-range electric vehicles in China. The Company started volume production of its first model, Li ONE, in November 2019. With Li ONE, the Company leverages its in-house technology to create value for its customers, focusing on range extension, smart technology, and autonomous driving solutions. Beyond Li ONE, the Company aims to expand its product line by developing new vehicles to target a broader consumer base.For more information, please visit: http://ir.lixiang.com.Safe Harbor StatementThis press release contains statements that may constitute forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expects, anticipates, aims, future, intends, plans, believes, estimates, likely to, and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Autos beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Autos strategies, future business development, and financial condition and results of operations; Li Autos limited operating history; risks associated with extended-range electric vehicles, Li Autos ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Autos ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Autos ability to compete successfully; Li Autos ability to build its brand and withstand negative publicity; cancellation of orders for Li Autos vehicles; Li Autos ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Autos filings with the SEC. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For investor and media inquiries, please contact:Li Auto Inc. Investor Relations Email: ir@lixiang.comThe Piacente Group, Inc. Yang Song Tel: +86-10-6508-0677 Email: Li@tpg-ir.comBrandi Piacente Tel: +1-212-481-2050 Email: Li@tpg-ir.com

Visit link:
Will Trevor Lawrence stay at Clemson to avoid the Jets? - Yahoo! Voices

Read More...

Spurs’ Becky Hammon honored with impressive San Antonio mural – Yahoo! Voices

November 2nd, 2020 3:51 am

GlobeNewswire

BEIJING, China, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Li Auto Inc. (Li Auto or the Company) (Nasdaq: LI), an innovator in Chinas new energy vehicle market, today announced that in October 2020 the Company delivered 3,692 Li ONEs, representing a steady increase compared to September. In October, the Company also achieved strong orders, setting a new monthly record. 2020 Q12020 Q22020 Q32020 JanOct Deliveries2,8966,6048,66021,852 As of October 31, 2020, the Company had 41 retail stores covering 36 cities. Going forward, the Company plans to continue strengthening its direct sales and servicing network to further bolster its footprint and market penetration in China.About Li Auto Inc.Li Auto Inc. is an innovator in Chinas new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric SUVs. Through innovative products, technology, and business model, the Company provides customers with safe, convenient, and cost-effective mobility solutions. Li Auto is the first to successfully commercialize extended-range electric vehicles in China. The Company started volume production of its first model, Li ONE, in November 2019. With Li ONE, the Company leverages its in-house technology to create value for its customers, focusing on range extension, smart technology, and autonomous driving solutions. Beyond Li ONE, the Company aims to expand its product line by developing new vehicles to target a broader consumer base.For more information, please visit: http://ir.lixiang.com.Safe Harbor StatementThis press release contains statements that may constitute forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expects, anticipates, aims, future, intends, plans, believes, estimates, likely to, and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Autos beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Autos strategies, future business development, and financial condition and results of operations; Li Autos limited operating history; risks associated with extended-range electric vehicles, Li Autos ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Autos ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Autos ability to compete successfully; Li Autos ability to build its brand and withstand negative publicity; cancellation of orders for Li Autos vehicles; Li Autos ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Autos filings with the SEC. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.For investor and media inquiries, please contact:Li Auto Inc. Investor Relations Email: ir@lixiang.comThe Piacente Group, Inc. Yang Song Tel: +86-10-6508-0677 Email: Li@tpg-ir.comBrandi Piacente Tel: +1-212-481-2050 Email: Li@tpg-ir.com

See original here:
Spurs' Becky Hammon honored with impressive San Antonio mural - Yahoo! Voices

Read More...

Total Student Enrollment of China New Higher Education Group Achieves Strong Organic Growth to a New Record High — Total Number of Enrolled Students…

November 2nd, 2020 3:51 am

Globe Newswire

Global Smart Food and Beverage Label Market to Reach $51. 9 Million by 2029. Market Report Coverage - Smart Food and Beverage Label. Market Segmentation.New York, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Smart Food and Beverage Label Market: Focus on Product Type, Application, Industry Analysis and Region Analysis Forecast, 2019-2029" - https://www.reportlinker.com/p05982085/?utm_source=GNW Product Type - RFID, NFC, Temperature Sensing Labels, Others Application - Food, Beverages Regional Segmentation North America U.S., Canada Europe Germany, France U.K. Asia-Pacific and Japan Australia and New Zealand, Japan, and India China Growth Drivers Growing Consumer Demands for Food Authentication Ability of Smart Labels to Enhance Food Safety and Reduce Food Waste Adoption and Implementation of Smart Food Labels by Major Food and Beverage Industry Manufacturers Market Challenges High Implementation Cost for the Smart Food Label Lack of Consumer Knowledge and Accessibility Disproportionality Market Opportunities Growing Confidence and Increasing Consumer Dependence on IoT Technologies Growing Need for Smart Inventory Management in Retail Industry Key Companies Profiled Avery Dennison Corporation, CCL Industries Inc., Honeywell International Inc., Label Insight, Inc., and Sato Holding Corporation, among others Key Questions Answered in this Report: What is the expected global smart food and beverage label market size in terms of value during the period 2018-2029? What are the labeling challenges faced by the food and beverage manufacturers? What is the on-going initiative to transform the global smart food and beverage label market? Which region is the largest market for the global smart food and beverage label market? What is the expected future scenario and the revenue generation by different geographical regions and countries in the smart food and beverage label market such as North America, South America, the U.K., Europe, the Middle East and Africa, China, and Asia-Pacific and Japan? What is the impact of COVID-19 on the smart food and beverage label market? Which product type is currently dominating the smart food and beverage label market, and which is likely to dominate in the future? What are the emerging trends in the global smart food and beverage label market? What are the market dynamics of the global smart food and beverage label market, including market drivers, restraints, and opportunities? What are the major market driving trends for the global smart food and beverage label market in terms business model, market consolidation, and new product offerings? Market Overview The adoption of smart labels has witnessed a sharp increase in the food industry as demand for product authentication and the ability to improve food safety continues to rise.Having connected packaging solutions like smart labels allows end consumers to access all traceable information across the supply chain. Smart labeling provides consumers with a digital source of nutrition, ingredients, allergen, and additional information which may or may not appear on the physical label printed on the packaging or attached to the product itself. Moreover, smart labels also help the consumer to pursue a wide range of products from design to shelf. The rising number of customers with access to packaged food is proliferating relative to the worlds population.The purchasing power of the customer for packaged food, on the other hand, is also growing. The growth in smart labeling is increasing with more and more expenditure on packaged food.Food authenticity evaluation has been required rapidly in the food and beverage industry. The evaluation ensures the originality and safety of any food product that comes into the market.This evaluation is achieved by using specific advanced methods and techniques. Some of the ways include Radio Frequency Identification (RFID) labels that can be attached to food products and can use electromagnetic fields to track products through the supply chain automatically. It brings traceability to the product, which is essential to trace the source of food and avoid counterfeit products. Within the research report, the market is segmented based on product type, application, and region. Each of these segments covers the markets snapshot of the propensity of market revenue, underlying patterns, and trends over the projected years by using analytics on the primary and secondary data obtained. Competitive Landscape The rise in the adoption of smart labeling in the food and beverage industry across the globe has led companies to invest in this industry.The competitive landscape for the smart food and beverage label market demonstrates an inclination toward companies adopting strategies such as product launches along with partnerships and collaborations. The result of the emerging strategies and developments is already surging the market in the form of product launch and developments. Driven by the rapid evolution of the food packaging sector, there has been swift growth in research and development activities by many important players in this market, leading to an increase in the number of product launches and developments since 2017. For instance, in July 2020, Label Insight, Inc. launched Explore Market Navigator, which will help CPG manufacturers improve online discoverability and increase the sales of their products. The business expansion strategy has also been significantly employed for the expansion in the smart food and beverage label market.As the global market continues to expand, businesses operating in this sector are forced to develop collaborative strategies in order to maintain themselves in an extremely competitive market. Key players are also engaging in business expansions in regions where there is a strong demand for smart labeled products.Industry leaders in this market are actively opting for this strategy to improve their market position. For instance, in April 2020, Label Insight, Inc., expanded its operations in the Canadian market to offer SmartLabel and accelerate the adoption of SmartLabel to support the needs of customers. Countries Covered North America U.S. Canada Europe Germany France U.K. China Asia-Pacific and Japan Japan Australia and New Zealand IndiaRead the full report: https://www.reportlinker.com/p05982085/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________CONTACT: Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original post here:
Total Student Enrollment of China New Higher Education Group Achieves Strong Organic Growth to a New Record High -- Total Number of Enrolled Students...

Read More...

Elis announces the acquisition of 3 laundries in Brazil – Yahoo Finance UK

November 2nd, 2020 3:51 am

Globe Newswire

Global Smart Food and Beverage Label Market to Reach $51. 9 Million by 2029. Market Report Coverage - Smart Food and Beverage Label. Market Segmentation.New York, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Smart Food and Beverage Label Market: Focus on Product Type, Application, Industry Analysis and Region Analysis Forecast, 2019-2029" - https://www.reportlinker.com/p05982085/?utm_source=GNW Product Type - RFID, NFC, Temperature Sensing Labels, Others Application - Food, Beverages Regional Segmentation North America U.S., Canada Europe Germany, France U.K. Asia-Pacific and Japan Australia and New Zealand, Japan, and India China Growth Drivers Growing Consumer Demands for Food Authentication Ability of Smart Labels to Enhance Food Safety and Reduce Food Waste Adoption and Implementation of Smart Food Labels by Major Food and Beverage Industry Manufacturers Market Challenges High Implementation Cost for the Smart Food Label Lack of Consumer Knowledge and Accessibility Disproportionality Market Opportunities Growing Confidence and Increasing Consumer Dependence on IoT Technologies Growing Need for Smart Inventory Management in Retail Industry Key Companies Profiled Avery Dennison Corporation, CCL Industries Inc., Honeywell International Inc., Label Insight, Inc., and Sato Holding Corporation, among others Key Questions Answered in this Report: What is the expected global smart food and beverage label market size in terms of value during the period 2018-2029? What are the labeling challenges faced by the food and beverage manufacturers? What is the on-going initiative to transform the global smart food and beverage label market? Which region is the largest market for the global smart food and beverage label market? What is the expected future scenario and the revenue generation by different geographical regions and countries in the smart food and beverage label market such as North America, South America, the U.K., Europe, the Middle East and Africa, China, and Asia-Pacific and Japan? What is the impact of COVID-19 on the smart food and beverage label market? Which product type is currently dominating the smart food and beverage label market, and which is likely to dominate in the future? What are the emerging trends in the global smart food and beverage label market? What are the market dynamics of the global smart food and beverage label market, including market drivers, restraints, and opportunities? What are the major market driving trends for the global smart food and beverage label market in terms business model, market consolidation, and new product offerings? Market Overview The adoption of smart labels has witnessed a sharp increase in the food industry as demand for product authentication and the ability to improve food safety continues to rise.Having connected packaging solutions like smart labels allows end consumers to access all traceable information across the supply chain. Smart labeling provides consumers with a digital source of nutrition, ingredients, allergen, and additional information which may or may not appear on the physical label printed on the packaging or attached to the product itself. Moreover, smart labels also help the consumer to pursue a wide range of products from design to shelf. The rising number of customers with access to packaged food is proliferating relative to the worlds population.The purchasing power of the customer for packaged food, on the other hand, is also growing. The growth in smart labeling is increasing with more and more expenditure on packaged food.Food authenticity evaluation has been required rapidly in the food and beverage industry. The evaluation ensures the originality and safety of any food product that comes into the market.This evaluation is achieved by using specific advanced methods and techniques. Some of the ways include Radio Frequency Identification (RFID) labels that can be attached to food products and can use electromagnetic fields to track products through the supply chain automatically. It brings traceability to the product, which is essential to trace the source of food and avoid counterfeit products. Within the research report, the market is segmented based on product type, application, and region. Each of these segments covers the markets snapshot of the propensity of market revenue, underlying patterns, and trends over the projected years by using analytics on the primary and secondary data obtained. Competitive Landscape The rise in the adoption of smart labeling in the food and beverage industry across the globe has led companies to invest in this industry.The competitive landscape for the smart food and beverage label market demonstrates an inclination toward companies adopting strategies such as product launches along with partnerships and collaborations. The result of the emerging strategies and developments is already surging the market in the form of product launch and developments. Driven by the rapid evolution of the food packaging sector, there has been swift growth in research and development activities by many important players in this market, leading to an increase in the number of product launches and developments since 2017. For instance, in July 2020, Label Insight, Inc. launched Explore Market Navigator, which will help CPG manufacturers improve online discoverability and increase the sales of their products. The business expansion strategy has also been significantly employed for the expansion in the smart food and beverage label market.As the global market continues to expand, businesses operating in this sector are forced to develop collaborative strategies in order to maintain themselves in an extremely competitive market. Key players are also engaging in business expansions in regions where there is a strong demand for smart labeled products.Industry leaders in this market are actively opting for this strategy to improve their market position. For instance, in April 2020, Label Insight, Inc., expanded its operations in the Canadian market to offer SmartLabel and accelerate the adoption of SmartLabel to support the needs of customers. Countries Covered North America U.S. Canada Europe Germany France U.K. China Asia-Pacific and Japan Japan Australia and New Zealand IndiaRead the full report: https://www.reportlinker.com/p05982085/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________CONTACT: Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Follow this link:
Elis announces the acquisition of 3 laundries in Brazil - Yahoo Finance UK

Read More...

Outcomes of Endoscopic Bariatric Therapies in Diabetic Patients – MD Magazine

October 31st, 2020 5:55 pm

Endoscopic bariatric therapies (EBTs) have been utilized for the treatment of obesity, but there has been limited data assessing their role in the treatment of diabetes.

A recent study presented at the annual American College of Gastroenterology (ACG) 2020 conference found that this procedure led to improved diabetes and weight loss parameters. The positive outcomes of EBTs in assessed diabetes patients were particularly noted for 3-12 months of use.

Additionally, the study determined that small bowel EBTs were more effective than gastric EBTs, which the investigators suggested might be due to different mechanisms of action.

The team, led by Benjamin Noor, MD, Resident at Ronald Reagan UCLA Medical Center, searched through MEDLINE, Embase, and Cochrane for randomized clinical trials and observational studies of EBTs.

Thus, included in their analysis were 1053 citations, 79 studies, and 7692 subjects.

Primary analyses included the pooled mean difference in baseline and final values in weight loss (percentage total weight loss, percentage excess weight loss, and BMI change from baseline) and glycemic control (fasting glucose, HbA1c) parameters.

Secondary analyses included changes in gut hormones measured by Hedges g. Specifically, they assessed the changes in ghrelin, glucagon-like peptide 1, peptide YY, and glucose-dependent insulinotropic peptide.

The results showed that EBT use for 3-12 months was associated with significant improvement in diabetes outcomes and weight loss indices in comparison with baseline or control groups. Although small bowel EBTs and gastric EBTs led to similar weight loss outcomes, greater improvements in diabetic parameters was associated with small bowel EBTs.

Furthermore, the authors noted that improvements in diabetes were associated with weight loss for gastric EBTs and an increase in postprandial glucagon-like peptide 1 and peptide YY for small bowel EBT.

In an interview with HCPLive, Noor provided further insight into these findings as well as the implications of them for a diabetic patient population.

View original post here:
Outcomes of Endoscopic Bariatric Therapies in Diabetic Patients - MD Magazine

Read More...

Addressing Racial Disparities in the Care of Children with Diabetes – Endocrinology Network

October 31st, 2020 5:55 pm

A podcast episode featuring a discussion related to racial and ethnic disparities in the care of children with type 1 diabetes.

This episode of the Endocrine Outlook features a conversation with Terri Lipman, PhD, CRNP, of the University of Pennsylvania. In the interview, Lipman discusses and offers perspective on a recent study she led examining disparities in insulin pump use among children with type 1 diabetes.

An analysis of data from a Philadelphia-based center, results indicate Hispanic and Black children were less likely than their non-Hispanic white counterparts. In the following podcast, Lipman, who serves as the assistant dean of community engagement at the School of Nursing at the University of Pennsylvania, sheds light on what she thinks are the most effective ways to confront these disparities at an individual and societal level.

The study referenced in this video, Insulin pump use in children with type 1 diabetes: Over a decade of disparities, was published in the Journal of Pediatric Nursing.

Continued here:
Addressing Racial Disparities in the Care of Children with Diabetes - Endocrinology Network

Read More...

Diabetes Diet: Guava (Amrood) Ki Sabzi Has All The Diabetes-Friendly Ingredients – Try The Recipe Today! – NDTV Food

October 31st, 2020 5:55 pm

Amrood ki sabzi recipe is great for diabetes diet.

Highlights

You are in the middle of any season; you'll find plenty of foods around to add to your diabetes diet. Diabetes or high blood sugar can be efficiently managed through a thoughtfully curated diet. Nature's bounty is full of low Glycaemic foods, which can come in handy to tweak our diet to suit our condition. Indian produce is brimming with fresh guavas this time of the year. For the unversed, this fruit is considered to be one of the best foods for diabetes diet.

The green-coloured fruit, with the seeded flesh inside, tastes great when eaten raw. You are required to remove the seeds though, to enjoy the sweet, juicy fruit with or without the peel. But sometimes, we unknowingly end up getting unripe guavas home and we just don't know what to with them. They are hard and a bit sour in taste. Instead of just tossing them out, turn those semi-ripe guavas into a delectable Indian curry, which will surprise you with its overwhelming flavours.

(Also Read:Love Guavas? Here Are 5 Ways You Can Turn Them Into Delish Desserts)

Promoted

Guava is a great fruit for diabetes diet.

Guava For Diabetes Diet I Health Benefits Of Guava

Besides being a low glycaemic food, guava has low sodium and high potassium content. According to the data of the United States Department of Agriculture (USDA), 100 gm serving of guava provides a whopping 417 gm of potassium. On top of it, guava is extremely rich in fibre and low in calories - all these features add up to make guava an essential addition to a diabetes diet.

How To Make Guava Curry Or Amrood Ki Sabzi:

First off, this guava dish is made a whole host of diabetes-friendly ingredients apart from guava: curd, tomatoes, fennel seeds, lemon juice and other healthy spices. Terrific, isn't it? Now, let's see how to make this amazing Indian-style guava curry.

Here's the step-by-step recipe of amrood ki sabzi with easy-to-follow cooking instructions.

Guavas are cooked in a tangy gravy of tomatoes and curd, seasoned with a range of spices like heeng, fennel seeds, cumin, turmeric powder etc, along with a smattering of lemon juice.

Pair the amrood ki sabzi with roti and enjoy a hearty Indian meal with your family.

About Neha GroverLove for reading roused her writing instincts. Neha is guilty of having a deep-set fixation with anything caffeinated. When she is not pouring out her nest of thoughts onto the screen, you can see her reading while sipping on coffee.

The rest is here:
Diabetes Diet: Guava (Amrood) Ki Sabzi Has All The Diabetes-Friendly Ingredients - Try The Recipe Today! - NDTV Food

Read More...

How digital care programs are revolutionizing employee diabetes care in the age of COVID – Employee Benefit Adviser

October 31st, 2020 5:55 pm

The modern diabetes care experience is broken. Today, patients with diabetes are asked to navigate a maze of specialty providers and bear the burden of complicated self-monitoring simply to keep their condition in check. The siloed care model isnt simply costly for patients and those responsible for their care; its demoralizing, exacerbating mental health effects of a chronic disease, and creating a reinforcing cycle of non-adherence.

On top of this, the COVID pandemic has made regular physician visits which normally serve as a critical touch point for diabetes patients less safe, and easily canceled. More than 200 healthcare professionals from 47 countries rank diabetes as the condition that will be most impacted by the reduction in healthcare resources due to COVID-19. According to a recent JAMA study, there have been substantial decreases in primary care delivery during the COVID pandemic, despite the rapid uptick in the use of virtual care visits. In the absence of effective in-person care for diabetes during the pandemic, and with synchronous telemedicine visits with physicians alone unable to provide the continuous support needed for effective diabetes self-management, forward-thinking employers are turning to digital care programs for diabetes to support their workers.

Read more: Springbuk, One Drop partner on diabetes management

In the last few months, weve seen how vital and motivating human connection is to our mental and physical health. COVID-19 has shone a light on the gaps in the traditional healthcare system, and the need for deeply human, digital solutions on a scale we couldnt have previously imagined. According to Evidation Health, gaps are looming on the horizon, with more than half of the individuals with type 2 diabetes, hypertension, migraine and many more conditions not yet substituting care.

Fortunately, digital diabetes care, often supported by a connected continuous glucose monitoring (CGM) system, offers a different path forward. Continuous glucose monitoring in combination with virtual coaching holds the potential to improve health outcomes for employees with diabetes during and after this pandemic. Weve always known that the best diabetes care has been focused on each patients individual needs. But COVID has made the need for personalized care even more important. Every individual has unique challenges they are dealing with during this new normal.

Read more: Here's your employee checklist for open enrollment

The expansion of digital diabetes care that incorporates continuous glucose monitoring along with proactive feedback from a coach and personalized resources can support people with diabetes as they navigate these challenges. By helping employees understand the connection between their day-to-day choices and glucose levels, effective digital diabetes care can serve as the connective tissues these individuals need to thrive, even in todays circumstances. By pairing accurate, and easily recorded, remote monitoring with personalized coaching guidance and all other elements of an accredited Diabetes Self-Management program, employers have the opportunity to both lift the burden of diabetes from their workforce, and make critical gains in employee health and productivity.

Chronic conditions like diabetes require constant, long term management with a focus on areas like reducing stress, taking medications, monitoring, and getting routine lab tests. Its why the CDC strongly recommends Diabetes Self Management Education and Support (DSMES) as a cost-effective tool to improve A1c levels, blood pressure, medication adherence, as well as reduced hospital admissions and healthcare costs. Yet access remains a major challenge. Only 6.8% of privately insured individuals used in-person DSMES programs and those percentages preceded the latest care disruptions discussed above.

As the pandemic makes regular clinic visits less accessible for patients, its critical that employees managing diabetes have access to support that fits their lifestyle, and is accessible when they need it most. Its never been more important to educate and empower employees to embrace high-value, sustainable care. Accessible, safe, and effective digital diabetes care holds the potential to improve health outcomes for people with diabetes and the employers and health plans that support them during and after this pandemic. By investing in deeply personalized digital care solutions, you can deliver not only a better employee experience, but ultimately better health outcomes and savings for your employees.

Excerpt from:
How digital care programs are revolutionizing employee diabetes care in the age of COVID - Employee Benefit Adviser

Read More...

Why diabetes is at the forefront of the COVID-19 pandemic – wtkr.com

October 31st, 2020 5:54 pm

HAMPTON ROADS, Va. - We all need to continue to be cautious as the COVID-19 pandemic still lingers all around us.

Diabetes is one of the medical conditions that has received additional attention during the COVID-19 pandemic.

"Diabetes in itself affects your immune system, and because of that impact and increased blood sugar, it lowers your ability for your immune system to work appropriately," said Dr. Ryan Light.

Light, a doctor with Greenbrier Family Medicine in Chesapeake, says those with diabetes don't have an increased risk of catching COVID-19 - but could have worse complications.

"You can see this in Asians who are thin, African Americans who are obese, or in really an combinations," said Light.

Type 2 is the most prevalent, says Light. That's when your body can't make enough insulin to convert glucose to energy.

In Type 1, more rare insulin-producing pancreatic cells are destroyed.

"As we age, our pancreas doesn't work quite as well, so we all see that we age and obesity increases. When that combines, it's the greatest risk for diabetes," Light said.

Data from the U.S. Centers for Disease Control and Prevention shows that three-fourts of people who died from COVID-19 had at least one preexisting condition. Diabetes was noted as underlying in 4 out of 10 patients.

"If your diabetes is well-controlled and you have an A1C of less than 7, you are doing a good job controlling diabetes, so it decreases your risk of having serious complications from COVID," Light said.

Light says diet and exercise are key to controlling diabetes, as well as regular doctor visits, proper handwashing, hygiene and mask-wearing to prevent the spread.

Original post:
Why diabetes is at the forefront of the COVID-19 pandemic - wtkr.com

Read More...

African Americans with Type 2 Diabetes, Kidney Disease at Higher Risk of COVID-19 Hospitalization – Michigan Medicine

October 31st, 2020 5:54 pm

Black patients are more likely to be hospitalized with COVID-19 than white patients with similar underlying health and socioeconomic conditions, according to a new Michigan Medicine study.

The research also found that having type 2 diabetes or kidney disease and living in high-population density areas are also associated with higher risk for COVID-19 hospitalization.

SEE ALSO: Keeping Our Patients Safe During COVID-19

The study indicates that racial disparities in COVID-19 hospitalization cannot be explained even after considering age, sex, neighborhood socioeconomic status and comorbidities, said Tian Gu, the study's first author and a doctoral candidate at the University of Michigans School of Public Health. Researchers did not find differences between African American and white patients in intensive care units and mortality outcomes.

MORE FROM THE LAB: Subscribe to our weekly newsletter

"Knowing risk profiles associated with severe COVID outcomes can help us protect ourselves and protect the most vulnerable," Gu said. "This calls for strategic action plans to eliminate health inequities that have persisted in our social system."

Gu and colleagues used electronic health data from Michigan Medicine hospitals. They looked at a cohort of 5,698 patients tested for or diagnosed with COVID-19 between March 10 and April 22. A group of randomly selected, untested individuals were included for comparison.

The researchers examined factors such as race/ethnicity, age, smoking, alcohol consumption, body mass index and residential-level socioeconomic characteristics. They also compared comorbidities such as circulatory disease, liver disease, type 2 diabetes and kidney disease.

"We were able to connect the geocoded residence to census tract data to derive these residential variables, which was a new aspect of our study," Gu said. "We also noticed some differences in the effect of obesity and prior cancer diagnosis having stronger association with COVID susceptibility in Black patients. On the other hand, the chances of hospitalization with overall comorbidity burden and type 2 diabetes were stronger in white patients."

Like Podcasts? Add the Michigan Medicine News Break oniTunes or anywhere you listen to podcasts.

Senior author Bhramar Mukherjee, professor and chair of the department of biostatistics at U-M's School of Public Health, said the results support targeted screening for elderly adults, members of the Black community and those with type 2 diabetes and kidney disease.

"Our findings highlight that poor COVID-19 outcomes are disproportionately associated with at-risk populations: elderly adults, those with preexisting conditions and those in population-dense communities," she said. "We call for increased investments in testing and prevention efforts in lower socioeconomic status, densely populated and racially diverse communities. It is these same communities that are home to a greater proportion of essential workers and thus need increased testing and protection."

The study is published in the current issue of JAMA Network Open.

SEE ALSO: Seeking Medical Care During COVID-19

Paper cited: Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System, JAMA Network Open. DOI: 10.1001/jamanetworkopen.2020.2519

View original post here:
African Americans with Type 2 Diabetes, Kidney Disease at Higher Risk of COVID-19 Hospitalization - Michigan Medicine

Read More...

Around the Diabetes Online Community: October 2020 Edition – Healthline

October 31st, 2020 5:54 pm

As we ease into November (aka National Diabetes Awareness Month), its worth taking a moment to look back on what October has brought us from the Diabetes Online Community(DOC). Theres been a whole lot of action, given the unpredictable nature of 2020 when anything and everything appears to be on tap. Despite todays Halloween theme, the posts weve seen have served to inspire and entertain more than scare us.

COVID-19 may be shutting down Halloween trick-or-treating this year, but there are still some fun diabetes-themed costumes on display for 2020! Check out this Halloween-y post at Type 1 Everyday Magic.

With the weather cooling down this time of year, these clever diabetes witch shirts and hoodies may be a perfect option to stay warm and snugly.

As the global health pandemic continues, its fascinating to read about experiences of people with diabetes (PWDs) participating in clinical research exploring the virus and possible vaccines. One of those type 1 study participants, Helene Cooper, shares her story in a recent podcast at Diabetes Connections.

The election season and political-everything can make the blood pressure rise, as Molly at Hugging the Cactus blog knows too well. She shares an important POV on a recent political claim about the cost of insulin.

Say hello to the Beta Cell Foundation, a new grassroots diabetes non-profit organization. Founded by fellow type 1 and podcaster Craig Stubing, it has some lofty goals of helping to fund community-based programs and activities that help PWDs. See their Twitter thread and Instagram posts for more details.

No way around it: This shirt is awesome! Thanks to D-peep Anita Nicole Brown for sharing it on Instagram.

How do you know what diabetes news is reliable? D-Moms Stacey Simms and Moira McCarthy Stanford share their thoughts on that topic in a new Diabetes Connections podcast.

Diabetes data can be both enlightening and hand-clenching at times, and its important to keep in mind that there are gatekeepers out there who make decisions about who can access your data. Our Australian type 1 friend Renza Scibilia has an insightful blog post on that topic.

Eating disorders can be compounded by diabetes because theres such a food focus in managing this condition, and our relationship with food can be, well, tricky. D-Dad Scott Benner at the Juicebox Podcast shares an important story on this issue, talking with a PWD whos experienced this herself.

Our hearts go out to OG diabetes advocate Scott Johnson, who lost his beloved father this past month. Read his moving tribute titled, He was the best I could ask for.

Congrats to D-peep Rob Howe over at Diabetics Doing Things, who recently got married and celebrated that special moment in life even with everything happening in the world. Be sure to wish Rob and his new wife the best!

If any particularly share-worthy D-posts catch your eye in November, please ping usviaemail, on Instagram@DiabetesMineNews,on Twitter@DiabetesMine, or on ourFacebook page.

See the article here:
Around the Diabetes Online Community: October 2020 Edition - Healthline

Read More...

Jewish Family Service and The Rothenberg Center offer Diabetes Self-Management Education and Support Program – Press of Atlantic City

October 31st, 2020 5:54 pm

I am better able to handle my diabetes, both physically and mentally, with the pointers discussed in class. For six weeks, it has been a life-changing experience, which I look forward to keeping for many years. Its a wonderful course.

The evidence-based workshop was developed by the Stanford University Patient Education Research Center and licensed by the State of New Jersey. Participants will receive a book, Living a Healthy Life with Chronic Conditions, to help manage diabetes within the context of their lifestyle.

For more information or to register for the Diabetes Self-Management Education & Support Program, contact Maggie Weaver, RN, at 609.350.8937 or mweaver@jfsatlantic.org.

About Jewish Family Service

Jewish Family Service of Atlantic & Cape May Counties (JFS) encourages strong families, thriving children, healthy adults, energized seniors and vital communities. With dozens of program areas, JFS specializes in counseling, mental health services, homeless programs, vocational services, adult and older adult services and also hosts an on-site food pantry. The agency impacts 8,000 lives throughout Atlantic and Cape May Counties each year.

JFS mission is to motivate and empower people to realize their potential and enhance their quality of life. In keeping with Jewish values and the spirit of tikkun olam (healing the world), JFS provides services with integrity, compassion, respect and professionalism regardless of their religion, race, gender, sexual orientation, ethnicity, age or background.

The rest is here:
Jewish Family Service and The Rothenberg Center offer Diabetes Self-Management Education and Support Program - Press of Atlantic City

Read More...

Prevalence of and Sociodemographic Disparities in Influenza Vaccination Among Adults With Diabetes in the United States – DocWire News

October 31st, 2020 5:54 pm

This article was originally published here

J Endocr Soc. 2020 Sep 24;4(11):bvaa139. doi: 10.1210/jendso/bvaa139. eCollection 2020 Nov 1.

ABSTRACT

National estimates describing the overall prevalence of and disparities in influenza vaccination among patients with diabetes mellitus (DM) in United States are not well described. Therefore, we analyzed the prevalence of influenza vaccination among adults with DM, overall and by sociodemographic characteristics, using the Medical Expenditure Panel Survey database from 2008 to 2016. Associations between sociodemographic factors and lack of vaccination were examined using adjusted logistic regression. Among adults with DM, 36% lacked influenza vaccination. Independent predictors of lacking influenza vaccination included age 18 to 39 years (odds ratio [OR] 2.54; 95% confidence interval [CI], 2.14-3.00), Black race/ethnicity (OR 1.29; 95% CI, 1.14-1.46), uninsured status (OR 1.88; 95% CI, 1.59-2.21), and no usual source of care (OR 1.61; 95% CI, 1.39-1.85). Nearly 64% individuals with 4 higher-risk sociodemographic characteristics lacked influenza vaccination (OR 3.50; 95% CI 2.79-4.39). One-third of adults with DM in the United States lack influenza vaccination, with younger age, Black race, and lower socioeconomic status serving as strong predictors. These findings highlight the continued need for focused public health interventions to increase vaccine coverage and utilization among disadvantaged communities.

PMID:33123656 | PMC:PMC7575128 | DOI:10.1210/jendso/bvaa139

See the original post:
Prevalence of and Sociodemographic Disparities in Influenza Vaccination Among Adults With Diabetes in the United States - DocWire News

Read More...

Stem Cell Umbilical Cord Blood Market to Enable the Stakeholders to Capitalize on the Prevailing Industry Opportunities with Investment Analysis By…

October 31st, 2020 5:54 pm

marketresearchhub Presents Stem Cell Umbilical Cord Blood Market Size, Status and Forecast 2020-2026 New Document to its Studies Database

This report, which has been published, is having a meaningful Stem Cell Umbilical Cord Blood market insight. It casts some lights on industry products and services. Along with those product applications, it also examined whether it reaches up to the end-users or not. This report on this Stem Cell Umbilical Cord Blood market has given an overall view of the recent technologies used and technological improvements. It also focuses on recent industry trends and which products are quite demanding from a customers perspective. This report is focused on every aspect of the forecast year 2026.

Stem Cell Umbilical Cord Blood Market dynamics analysis

This report is representing a whole market scenario on a global basis. In this report, we can also find the analysis growth of industries. Through this report, we can easily interpreter the level of market competition, different pricing models, the latest market trends, customer demand, etc. This report acknowledges the revenue model and market expansion of this Stem Cell Umbilical Cord Blood market. If you want to get that full market information, then this report can help you. It also gives a comprehensive knowledge about the demand and supply graph. Suppose that demand curves moved downward, then from this report, you can know about those factors responsible for its decline. Accordingly, you can know the responsible factors for the rising curve. This Stem Cell Umbilical Cord Blood market report gives a total knowledge about the market trend and improves its strategies and pricing model.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2806688&source=atm

In the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell Therapy for Osteoarthritis market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyMesoblastRegeneusU.S. Stem CellAnterogenAsterias Biotherapeutics

Research and Methodology

For the research, the Stem Cell Umbilical Cord Blood markets research teams are adopted various high-end techniques. Industry best analysts are worked on this report. They collected data from various reliable sources and have taken samples of different market segments. They utilize both qualitative and quantitative data in this report. All data are based on primary sources, which are focused on the assessment year 2020-2026. For wise decision-making, they have also done SWOT analysis, which can also help them know their predicted future results. This report also helps to develop Stem Cell Umbilical Cord Blood market growth by improvising its strategic models.

segment by Type, the product can be split intoMonotherapyCombination Therapy

Market segment by Application, split intoOsteoarthritis (unspecified)Knee OsteoarthritisShoulder OsteoarthritisHip Osteoarthritis

Based on regional and country-level analysis, the Stem Cell Therapy for Osteoarthritis market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

Regional and Country-level Analysis

The Stem Cell Umbilical Cord Blood market is analysed and market size information is provided by regions (countries).

The key regions covered in the Stem Cell Umbilical Cord Blood market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2806688&licType=S&source=atm

Table Of Content Covered In this Stem Cell Umbilical Cord Blood Market Report:

1 Report Overview

2 Global Growth Trends by Regions

3 Competition Landscape by Key Players

4 Breakdown Data by Type (2015-2026)

5 Breakdown Data by Application (2015-2026)

6 North America

7 Europe

8 China

9 Japan

10 Southeast Asia

11 India

12 Central & South America

13Key Players Profiles

14Analysts Viewpoints/Conclusions

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details

The rest is here:
Stem Cell Umbilical Cord Blood Market to Enable the Stakeholders to Capitalize on the Prevailing Industry Opportunities with Investment Analysis By...

Read More...

Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 – PRnews Leader

October 31st, 2020 5:54 pm

Overview for Adult Stem Cells Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

Adult Stem Cells Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024The study of Adult Stem Cells market is a compilation of the market of Adult Stem Cells broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Adult Stem Cells industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Adult Stem Cells industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Adult Stem Cells Market report @ https://hongchunresearch.com/request-a-sample/92343

Key players in the global Adult Stem Cells market covered in Chapter 4:Intellicell Biosciences Inc.GlobalstemNeurogenerationCapricor Inc.Caladrius Biosciences Inc.Mesoblast Ltd.CelyadJuventas Therapeutics Inc.Cytori Therapeutics Inc.Cellular Dynamics InternationalEpistem Ltd.Brainstorm Cell Therapeutics Inc.Cellerant Therapeutics Inc.Hybrid Organ GmbhCellerix SaNeuralstemInternational Stem Cell Corp.Beike Biotechnology Co. Ltd.Biotime Inc.Gamida Cell Ltd.Clontech

In Chapter 11 and 13.3, on the basis of types, the Adult Stem Cells market from 2015 to 2026 is primarily split into:Epithelial Stem CellsHematopoietic Stem Cells

In Chapter 12 and 13.4, on the basis of applications, the Adult Stem Cells market from 2015 to 2026 covers:Neurodegenerative DiseasesHeart DiseasesBone DiseasesOthers

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

For a global outreach, the Adult Stem Cells study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Adult Stem Cells Market Report with [emailprotected]https://hongchunresearch.com/report/adult-stem-cells-market-size-2020-92343

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Adult Stem Cells Market

Chapter Four: Players Profiles

Chapter Five: Global Adult Stem Cells Market Analysis by Regions

Chapter Six: North America Adult Stem Cells Market Analysis by Countries

Chapter Seven: Europe Adult Stem Cells Market Analysis by Countries

Chapter Eight: Asia-Pacific Adult Stem Cells Market Analysis by Countries

Chapter Nine: Middle East and Africa Adult Stem Cells Market Analysis by Countries

Chapter Ten: South America Adult Stem Cells Market Analysis by Countries

Chapter Eleven: Global Adult Stem Cells Market Segment by Types

Chapter Twelve: Global Adult Stem Cells Market Segment by Applications 12.1 Global Adult Stem Cells Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Adult Stem Cells Sales and Market Share by Applications (2015-2020) 12.1.2 Global Adult Stem Cells Revenue and Market Share by Applications (2015-2020) 12.2 Neurodegenerative Diseases Sales, Revenue and Growth Rate (2015-2020) 12.3 Heart Diseases Sales, Revenue and Growth Rate (2015-2020) 12.4 Bone Diseases Sales, Revenue and Growth Rate (2015-2020) 12.5 Others Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Adult Stem Cells Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/92343

List of tablesList of Tables and Figures Table Global Adult Stem Cells Market Size Growth Rate by Type (2020-2026) Figure Global Adult Stem Cells Market Share by Type in 2019 & 2026 Figure Epithelial Stem Cells Features Figure Hematopoietic Stem Cells Features Table Global Adult Stem Cells Market Size Growth by Application (2020-2026) Figure Global Adult Stem Cells Market Share by Application in 2019 & 2026 Figure Neurodegenerative Diseases Description Figure Heart Diseases Description Figure Bone Diseases Description Figure Others Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Adult Stem Cells Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Adult Stem Cells Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Adult Stem Cells Figure Production Process of Adult Stem Cells Figure Manufacturing Cost Structure of Adult Stem Cells Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Intellicell Biosciences Inc. Profile Table Intellicell Biosciences Inc. Production, Value, Price, Gross Margin 2015-2020 Table Globalstem Profile Table Globalstem Production, Value, Price, Gross Margin 2015-2020 Table Neurogeneration Profile Table Neurogeneration Production, Value, Price, Gross Margin 2015-2020 Table Capricor Inc. Profile Table Capricor Inc. Production, Value, Price, Gross Margin 2015-2020 Table Caladrius Biosciences Inc. Profile Table Caladrius Biosciences Inc. Production, Value, Price, Gross Margin 2015-2020 Table Mesoblast Ltd. Profile Table Mesoblast Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Celyad Profile Table Celyad Production, Value, Price, Gross Margin 2015-2020 Table Juventas Therapeutics Inc. Profile Table Juventas Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Cytori Therapeutics Inc. Profile Table Cytori Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Cellular Dynamics International Profile Table Cellular Dynamics International Production, Value, Price, Gross Margin 2015-2020 Table Epistem Ltd. Profile Table Epistem Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Brainstorm Cell Therapeutics Inc. Profile Table Brainstorm Cell Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Cellerant Therapeutics Inc. Profile Table Cellerant Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Hybrid Organ Gmbh Profile Table Hybrid Organ Gmbh Production, Value, Price, Gross Margin 2015-2020 Table Cellerix Sa Profile Table Cellerix Sa Production, Value, Price, Gross Margin 2015-2020 Table Neuralstem Profile Table Neuralstem Production, Value, Price, Gross Margin 2015-2020 Table International Stem Cell Corp. Profile Table International Stem Cell Corp. Production, Value, Price, Gross Margin 2015-2020 Table Beike Biotechnology Co. Ltd. Profile Table Beike Biotechnology Co. Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Biotime Inc. Profile Table Biotime Inc. Production, Value, Price, Gross Margin 2015-2020 Table Gamida Cell Ltd. Profile Table Gamida Cell Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Clontech Profile Table Clontech Production, Value, Price, Gross Margin 2015-2020 Figure Global Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Global Adult Stem Cells Revenue ($) and Growth (2015-2020) Table Global Adult Stem Cells Sales by Regions (2015-2020) Table Global Adult Stem Cells Sales Market Share by Regions (2015-2020) Table Global Adult Stem Cells Revenue ($) by Regions (2015-2020) Table Global Adult Stem Cells Revenue Market Share by Regions (2015-2020) Table Global Adult Stem Cells Revenue Market Share by Regions in 2015 Table Global Adult Stem Cells Revenue Market Share by Regions in 2019 Figure North America Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Europe Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Asia-Pacific Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Middle East and Africa Adult Stem Cells Sales and Growth Rate (2015-2020) Figure South America Adult Stem Cells Sales and Growth Rate (2015-2020) Figure North America Adult Stem Cells Revenue ($) and Growth (2015-2020) Table North America Adult Stem Cells Sales by Countries (2015-2020) Table North America Adult Stem Cells Sales Market Share by Countries (2015-2020) Figure North America Adult Stem Cells Sales Market Share by Countries in 2015 Figure North America Adult Stem Cells Sales Market Share by Countries in 2019 Table North America Adult Stem Cells Revenue ($) by Countries (2015-2020) Table North America Adult Stem Cells Revenue Market Share by Countries (2015-2020) Figure North America Adult Stem Cells Revenue Market Share by Countries in 2015 Figure North America Adult Stem Cells Revenue Market Share by Countries in 2019 Figure United States Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Canada Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Mexico Adult Stem Cells Sales and Growth (2015-2020) Figure Europe Adult Stem Cells Revenue ($) Growth (2015-2020) Table Europe Adult Stem Cells Sales by Countries (2015-2020) Table Europe Adult Stem Cells Sales Market Share by Countries (2015-2020) Figure Europe Adult Stem Cells Sales Market Share by Countries in 2015 Figure Europe Adult Stem Cells Sales Market Share by Countries in 2019 Table Europe Adult Stem Cells Revenue ($) by Countries (2015-2020) Table Europe Adult Stem Cells Revenue Market Share by Countries (2015-2020) Figure Europe Adult Stem Cells Revenue Market Share by Countries in 2015 Figure Europe Adult Stem Cells Revenue Market Share by Countries in 2019 Figure Germany Adult Stem Cells Sales and Growth Rate (2015-2020) Figure UK Adult Stem Cells Sales and Growth Rate (2015-2020) Figure France Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Italy Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Spain Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Russia Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Asia-Pacific Adult Stem Cells Revenue ($) and Growth (2015-2020) Table Asia-Pacific Adult Stem Cells Sales by Countries (2015-2020) Table Asia-Pacific Adult Stem Cells Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Adult Stem Cells Sales Market Share by Countries in 2015 Figure Asia-Pacific Adult Stem Cells Sales Market Share by Countries in 2019 Table Asia-Pacific Adult Stem Cells Revenue ($) by Countries (2015-2020) Table Asia-Pacific Adult Stem Cells Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Adult Stem Cells Revenue Market Share by Countries in 2015 Figure Asia-Pacific Adult Stem Cells Revenue Market Share by Countries in 2019 Figure China Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Japan Adult Stem Cells Sales and Growth Rate (2015-2020) Figure South Korea Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Australia Adult Stem Cells Sales and Growth Rate (2015-2020) Figure India Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Southeast Asia Adult Stem Cells Sales and Growth Rate (2015-2020) Figure Middle East and Africa Adult Stem Cells Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read the rest here:
Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 - PRnews Leader

Read More...

Global Stem Cell Media Market Dynamics Analysis, Production, Supply and Demand, Covered in the Latest Research 2020-2025 – re:Jerusalem

October 31st, 2020 5:54 pm

The most recent Global Stem Cell Media Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 includes some noteworthy developments with accurate market estimates. The report spotlights major statistics of the current industry state with developments and opportunities available in the market. The research highlights market business status, presents worth and volume, market product type, key players, and regional analysis. The study presented here comes out as a highly reliable source of information and data on the global Stem Cell Media market. It then analyses the world market estimates and forecasts of all the given segments on global as well as regional levels. The report focuses on market trends, supply chain trends, leading players, key developments, and future strategies.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Report Synopsis:

Players will also be able to know about future market challenges, distribution scenarios, product pricing changes, and other related factors. Inputs from industry experts have been collected to deliver detailed market analysis. The report encapsulates factors such as market outline, type-based analysis of global Stem Cell Media market, application analysis, and end-use. Top competitors are monitored by following the key product positioning within the market framework. The market analysis report offers market share, demand, and supply ratio, supply chain analysis, and import/export details.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/113885

The market report comprises of most-detailed market segmentation, analysis of major global Stem Cell Media market players, trends in consumer and supply chain dynamics, and insights about new geographical markets. Other factors such as supply chain, downstream buyers, and sourcing strategy have been assessed to provide a comprehensive view of the market.

For the competitor segment, the report includes global key players of Stem Cell Media are included: Thermo Fisher, CellGenix, Lonza, STEMCELL Technologies, Corning, Merck Millipore, PromoCell, Miltenyi Biotec, GE Healthcare, Takara, HiMedia

Market segmentation, by product types: Pluripotent Stem Cell Culture, Hematopoietic Stem Cell Culture, Mesenchymal Stem Cell Culture, Others

Market segmentation, by applications: Scientific Research, Industrial Production

Based on segmentation, the market report is made up of an in-depth investigation of the leading regions, including: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/113885/global-stem-cell-media-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

The Scope of This Global Market Report:

Moreover, data related to the returns held by each product segment, and information about the consumption patterns of the product are provided in the report. This research report recognizes the industrial base, productivity, manufacturers, and recent trends, features, which are the basic requirements in the global Stem Cell Media market to enlarge the companies and promote financial growth.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Follow this link:
Global Stem Cell Media Market Dynamics Analysis, Production, Supply and Demand, Covered in the Latest Research 2020-2025 - re:Jerusalem

Read More...

Comprehensive Report on NK Cell Therapy and Stem Cell Therapy Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Chipscreen…

October 31st, 2020 5:53 pm

NK Cell Therapy and Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

NK Cell Therapy and Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of this report:

https://www.a2zmarketresearch.com/sample?reportId=325609

Top Key Players Profiled in this report are:

Chipscreen Biosciences, Innate Pharma SA, Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, JCR Pharmaceutical, Altor BioScience Corporation, Affimed NV, Takeda Pharmaceutical, Pharmicell, Medi-post, NuVasive, Anterogen

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global NK Cell Therapy and Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the NK Cell Therapy and Stem Cell Therapy markets trajectory between forecast periods.

Get up to 30% Discount of this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=325609

Global NK Cell Therapy and Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

NK Cell TherapyStem Cell Therapy

Market Segmentation by Application:

Hospital & clinicsRegenerative medicine centersDiagnostic centersResearch institutesOthers

Regions Covered in the Global NK Cell Therapy and Stem Cell Therapy Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Reasons for buying this report:

Table of Contents:

Global NK Cell Therapy and Stem Cell Therapy Market Research Report 2020

Chapter 1 NK Cell Therapy and Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global NK Cell Therapy and Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=325609

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

More:
Comprehensive Report on NK Cell Therapy and Stem Cell Therapy Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Chipscreen...

Read More...

Mesenchymal Stem Cells Market Augmented Expansion to Be Registered by 2020-2025 – Eurowire

October 31st, 2020 5:53 pm

The research report on Mesenchymal Stem Cells Market gives thorough insights regarding various key trends that shape the industry expansion with regards to regional perspective and competitive spectrum. Furthermore, the document mentions the challenges and potential restrains along with latent opportunities which may positively impact the market outlook in existing and untapped business spaces. Moreover, it presents the case studies, including the ones related to COVID-19 pandemic, to convey better understanding of the industry to all the interested parties.

The recent market trend of increasingly using Mesenchymal Stem Cells for understanding the development of a disease extensively fuel the growth of this market in the coming years. Another trend that will aid the growth of the global Mesenchymal Stem Cells market is the escalating demand for personalized medicine. Extensive investments are being made by various organizations, pharmaceutical companies, and governments for the research and development of drugs, and this is another trend that is benefiting the growth of the global Mesenchymal Stem Cells market. This is because Mesenchymal Stem Cells techniques enable researchers to compare Mesenchymal Stem Cells changes between disease samples and normal samples. Public health can thus be analyzed as the changes in Mesenchymal Stem Cells are influenced by internal biological system and environment directly.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/3921426?utm_source=Nilesh-EW

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Advanced Cell Technology Incorporated, Stem cell technologies Inc., Stemedica Cell Technologies, Inc., Cyagen Biosciences Inc., EMD Millipore Corporation, ScienCell Research Laboratories., Cytori Therapeutics Inc., Cell Applications, Inc., Axol Bioscience Ltd., Aastrom Biosciences, BrainStorm Cell Therapeutics., R&D Systems, Inc., Genlantis, Inc., Celprogen, Inc..

Mesenchymal Stem Cells Market Segmentation:

In market segmentation by types of Mesenchymal Stem Cells, the report covers-

Bone MarrowUmbilical Cord BloodPeripheral BloodLung TissueSynovial TissuesAmniotic FluidsAdipose Tissues

In market segmentation by applications of the Mesenchymal Stem Cells, the report covers the following uses-

InjuriesDrug DiscoveryCardiovascular InfractionOthers

Regional Analysis for Mesenchymal Stem Cells Market-:

1) North America- (United States, Canada)

2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)

3) Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)

4) Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)

5) Latin America- (Brazil, Mexico, Argentina, Colombia, Chile, Peru)

The report provides insights on the following pointers :

Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market

NOTE: Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/3921426?utm_source=Nilesh-EW

Table of Content

Chapter 1 Mesenchymal Stem Cells Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global Mesenchymal Stem Cells Market, by Type

Chapter 5 Mesenchymal Stem Cells Market, by Application

Chapter 6 Global Mesenchymal Stem Cells Market Analysis by Regions

Chapter 7 North America Mesenchymal Stem Cells Market Analysis by Countries

Chapter 8 Europe Mesenchymal Stem Cells Market Analysis by Countries

Chapter 9 Asia Pacific Mesenchymal Stem Cells Market Analysis by Countries

Chapter 10 Middle East and Africa Mesenchymal Stem Cells Market Analysis by Countries

Chapter 11 South America Mesenchymal Stem Cells Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global Mesenchymal Stem Cells Market Forecast

Chapter 15 New Project Feasibility Analysis

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:

Mr. Abhishek Paliwal

Big Market Research

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452

E-mail: [emailprotected]

See original here:
Mesenchymal Stem Cells Market Augmented Expansion to Be Registered by 2020-2025 - Eurowire

Read More...

Page 314«..1020..313314315316..320330..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick